Autolus Therapeutics (AUTL)

• Market cap: $407M
• 1 day: -4.38%
• 5 days: -4.97%
• 1 month: 9.29%
• 3 months: 4.79%
• 6 months: 2%
• Year to date: -18.18%
• 1 year: 1.32%
• 5 years: -71.82%
• 10 years: -93.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Employees: 752